US HB931 | 2015-2016 | 114th Congress
Status
Spectrum: Partisan Bill (Democrat 8-0)
Status: Introduced on February 12 2015 - 25% progression, died in committee
Action: 2015-02-13 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Status: Introduced on February 12 2015 - 25% progression, died in committee
Action: 2015-02-13 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]
Summary
HEAL Act Helping Effective Antibiotics Last Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to allow the Food and Drug Administration (FDA) to approve an antibacterial drug or biological product that is intended to treat a serious or life-threatening condition only for treating a well-defined population of patients. To be approved, the antibacterial product must produce superior outcomes over available therapies in the well-defined patient population. A product approved by this pathway must include in its prescribing information the population of patients expected to benefit from using the product and the method for identifying members of that population. The FDA must require each product to have a risk evaluation and mitigation strategy. The Centers for Disease Control and Prevention must monitor changes to bacterial drug resistance and changes to patient outcomes caused by bacterial drug resistance. Upon approval of antibacterial products, the FDA must identify susceptibility test interpretive criteria (the drug concentrations where a type of bacteria is categorized as susceptible, intermediate, or resistant) and update the criteria as needed based upon evidence of changes in patient outcomes. To be eligible for an exclusivity period extension, a qualified infectious disease product must be demonstrated to produce superior outcomes over available therapies. The FDA must issue guidance on the development of target product profiles for antibacterial drugs.
Title
HEAL Act Helping Effective Antibiotics Last Act of 2015
Sponsors
Rep. Rosa DeLauro [D-CT] | Rep. Louise Slaughter [D-NY] | Rep. Grace Meng [D-NY] | Rep. Keith Ellison [D-MN] |
Rep. Raul Grijalva [D-AZ] | Rep. Peter DeFazio [D-OR] | Rep. Eleanor Norton [D-DC] | Rep. Betty McCollum [D-MN] |
History
Date | Chamber | Action |
---|---|---|
2015-02-13 | House | Referred to the Subcommittee on Health. |
2015-02-12 | House | Referred to the House Committee on Energy and Commerce. |
2015-02-12 | House | Introduced in House |
Subjects
Administrative law and regulatory procedures
Administrative remedies
Consumer affairs
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Government information and archives
Health
Health information and medical records
Infectious and parasitic diseases
Licensing and registrations
Medical research
Prescription drugs
Administrative remedies
Consumer affairs
Department of Health and Human Services
Drug safety, medical device, and laboratory regulation
Food and Drug Administration (FDA)
Government information and archives
Health
Health information and medical records
Infectious and parasitic diseases
Licensing and registrations
Medical research
Prescription drugs
US Congress State Sources
Type | Source |
---|---|
Summary | https://www.congress.gov/bill/114th-congress/house-bill/931/all-info |
Text | https://www.congress.gov/114/bills/hr931/BILLS-114hr931ih.pdf |